PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Infliximab - Pouchitis

PAD Profile : Infliximab - Pouchitis

Keywords :
biosimilar, cytokine modulator, monoclonal antibody, mab, anti-TNF, TNF-alpha, subcutaneous, pre-filled pen, pre-filled syringe, inflammation of the ileal reservoir
Brand Names Include :
Inflectra, Remsima, Flixabi, Zessly

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 October 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve infliximab for chronic pouchitis after treatment with steroids and/or antibiotics in combination.

Infliximab will be assigned a RED traffic light status on the Prescribing Advisory Database (PAD)

Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More